 Healio | Lenalidomide, rituximab combination shows promise in CLL Healio The study regimen included rituximab 375 mg/m2 IV administered weekly during cycle one and on day 1 of cycles three to 12. Oral lenalidomide was initiated on day 9 of cycle one at 10 mg and was administered daily continuously. The cycles were 28 days. |
